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Abstract
The complement and coagulation systems closely interact with each other. These interac-
tions are believed to contribute to the proinflammatory and prothrombotic environment
involved in the development of thrombotic complications in many diseases. Complement
MASP-1 (mannan-binding lectin-associated serine protease-1) activates coagulation fac-
tors and promotes clot formation. However, this was mainly shown in purified or plasma-
based static systems. Here we describe the role of MASP-1 and complement activation in
fibrin clot formation in a microvascular, whole blood flow model. This microfluidic system
simulates blood flow through microvessels at physiological flow and shear rates and repre-
sents the closest model system to human physiology so far. It features parallel microchan-
nels cultured with endothelial cells in a transparent microfluidic chip allowing real-time
evaluation of clot formation by confocal microscopy. To test their effects on clot formation,
we added the following activators or inhibitors (individually or in combination) to whole blood
and performed perfusion experiments: rMASP-1cf (recombinant active form of MASP-1),
complement activator zymosan, selective MASP-1 inhibitor SGMI-1 (based on the Schisto-
cerca gregaria protease inhibitor scaffold), classical pathway inhibitor rSALO (recombinant
salivary anti-complement from Lutzomyia longipalpis). Addition of rMASP-1cf resulted in
accelerated fibrin clot formation while addition of SGMI-1 delayed it. Complement activation
by zymosan led to increased clot formation and this effect was partially reversed by addition
of rSALO and almost abolished in combination with SGMI-1. We show for the first time a
strong influence of MASP-1, complement activation and pathway-specific inhibition on coag-
ulation in a microvascular flow system that is closest to human physiology, further underpin-
ning the in vivo relevance of coagulation and complement interactions.
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Introduction
Cardio- and cerebrovascular diseases (CVDs) still represent the leading cause of morbidity
and mortality in industrialized countries, despite the availability of modern therapies. The
development of CVDs is a consequence of a proinflammatory and prothrombotic vascular
environment that may be further promoted by dysregulation of the complement system and
its interactions with the coagulation system. Therefore, targeting the complement system and
its interactions with coagulation may in the future represent a promising novel approach in
the prevention and therapy of CVDs.
The complement and coagulation systems share a common evolutionary origin, they show
many similarities, and there is increasing evidence for their close interaction in order to pro-
tect the body in case of injury and infection. The extensive cross-talk between complement
and coagulation is reciprocal and occurs on all levels of their cascades, and therefore needs
tight regulation. A dysregulation of one or the other cascade may lead to an excessive activa-
tion of both systems, which can become manifest in many diseases including infection, sepsis,
diabetes and atherosclerosis [1–3].
The complement system is an essential part of the innate immune system and serves to
eliminate pathogens from the circulation, it mediates the inflammatory response and is
involved in the clearance of apoptotic host cells. The lectin pathway (LP) is one of three activa-
tion pathways, all of which lead to a common downstream pathway that triggers the three
main effector functions of the complement system: i) Enhancing the inflammatory process by
anaphylatoxins, ii) formation of the membrane attack complex (MAC, C5b-9) on cell surfaces,
and iii) opsonizing surfaces, thereby marking them for clearance [4].
The LP is activated by binding of specific structures on microorganisms and altered self-
surfaces to mannose-binding lectin (MBL) and other collectins or ficolins which are com-
plexed in a diverse manner with the MBL-associated serine proteases (MASPs) MASP-1,
MASP-2 or MASP-3. Upon binding of a target, MASP-1 becomes activated and changes its
conformation, subsequently leading to an inter- and intra-complex activation of MASP-2 and
additional MASP-1 [5]. Both activated MASP-1 and MASP-2 promote the formation of the
C3-convertase via C2 and C4 cleavage and thereby trigger the effector functions of the comple-
ment system [4,6].
In recent years various interactions between the lectin pathway (LP) of complement and the
coagulation system have been demonstrated. Among the LP components, especially MASP-1
has moved into the focus of interest: It has been shown that MASP-1 is more closely related to
thrombin than to other complement serine proteases in terms of its structural features and its
broad substrate specificity [7,8]. Besides its substrates in the LP, MASP-1 is also able to cleave
thrombin substrates such as fibrinogen, blood coagulation factor XIII (FXIII), thrombin-acti-
vatable fibrinolysis inhibitor (TAFI), and protease-activated receptor 1 (PAR-1) on endothelial
cells [9–11]. Furthermore, we have recently demonstrated that MASP-1 is able to induce clot
formation in a prothrombin-dependent manner in thrombelastographic experiments and have
presented the first model of MASP-1-mediated prothrombin activation [12,13]. MASP-1 has
also been shown to be activated by platelets and fibrin formation in a prothrombotic environ-
ment [14] and suggested to modulate clot structure and resistance to fibrinolysis [9].
In vivo studies using animal models have provided strong evidence for an involvement of
MASP-1 in coagulation. Takahashi et al. showed that MBL and MASP-1 knockout mice exhib-
ited a prolonged bleeding time upon tail tip excision [15], while another study demonstrated
that mice deficient in MBL and MASP-1 show decreased thrombus formation in FeCl3-
induced thrombogenesis [16]. Furthermore, we have shown that MASP-1 and MASP-2 plasma
levels are altered in patients with CVD [17].
MASP-1 in a microvascular flow model
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So far, experiments studying the direct and indirect interactions of MASP-1 with the
human coagulation system have mainly been conducted in purified or plasma-based static sys-
tems [9,14,18]. Tsai et al. reported the development of a microfluidic model which accurately
simulates microvascular blood vessels in a way that is very close to human physiology [19]. It
allows real-time confocal microscopic observation of blood flow and clot formation in parallel
channels (dimensions 50 μm x 100 μm) in a transparent silicone chip coated with a viable
endothelial cell monolayer perfused with whole blood at physiological flow and shear rates (1–
4 dyne/cm2). The four parallel channels allow simultaneous observation of several samples,
e.g. with addition of different activators or inhibitors, from the same donor under the same
experimental conditions making this model an ideal tool to observe differences in clot forma-
tion. The model can easily be adapted for different experimental settings [20]. It has been vali-
dated for studies on platelet mechanics, hematological diseases and interactions between
coagulation and the immune system [19,21–23].
For the present study, we have established this model in our laboratory in close collabora-
tion with the group of Prof Wilbur Lam and used it to investigate the relevance of MASP-1
and complement activation for whole blood clot formation under flow conditions for the first
time. We also show for the first time that MASP-1 and pathway-specific complement inhibi-
tion reduces clot formation in this close-to-physiological environment.
Materials and methods
Recombinant MASP-1 and specific inhibitors
So far it has not been possible to express or purify reasonable amounts of pure and stable full-
length MASP-1; therefore, we have used a truncated recombinant form of MASP-1 termed
rMASP-1cf (recombinant MASP-1 catalytic fragment) for our experiments. rMASP-1cf com-
prises the catalytic active C-terminal domains CCP1-CCP2-SP while lacking the N-terminal
domains CUB1-EGF-CUB2 [7]. In a recent work, we showed that rMASP-1cf and full-length
MASP-1 have the same effects on clot formation [12]. In our experiments we used a final con-
centration of 10 μg/ml rMASP-1cf, which corresponds to the average concentration measured
in sera of healthy adult donors [24].
SGMI-1 (Schistocerca gregaria protease inhibitor (SGPI)-based MASP inhibitor-1), MW
4076 Da, is a monospecific inhibitor for MASP-1 [25]. SGMI-1 has been shown to have no sig-
nificant effect on blood coagulation in the standard coagulation assays thrombin time (TT),
prothrombin time (PT), and activated partial thromboplastin time (APTT) [26].
rSALO (recombinant salivary anti-complement from Lutzomyia longipalpis), MW 10.8
kDa, inhibits the activation of the classical complement pathway (CP). The exact mode of
action of the molecule is unknown so far, however it has been shown to inhibit the CP-depen-
dent deposition of C4b, C3b, C5b and C9, while not interfering with the activities of the lectin
pathway, the alternative pathway (AP) and the proteases of the hemostatic system. It is
assumed that rSALO interferes with CP activation by either displacing C1r or C1s from the C1
complex or by inhibiting the C1r activity [27].
The microvascular flow model
The wafer serving as template for the chip was produced by imprinting a specific microchannel
pattern onto a silicon photomask at the Georgia Institute of Technology and Emory University
of School of Medicine in Atlanta, Georgia, USA. The single-use chips were then produced in
our lab at the University of Bern: The wafer was covered with a solution of polydimethylsilox-
ane (PDMS) and its curing agent (Sylgard 184 silicone elastomer kit; Dow Corning, Midland,
Michigan, USA) at a thickness of 1 cm and cured over-night at 60˚C. Subsequently, holes of
MASP-1 in a microvascular flow model
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1.42 mm diameter were punched into the chip connecting the parallel channels with the sur-
face of the device. The bottom side bearing the microchannels (dimensions 50 μm x 100 μm)
was subsequently sealed with a thin layer of PDMS (2 mm) by plasma bonding (basic plasma
cleaner, Harrick Plasma, Ithaca, New York, USA). A finished chip and its schematic structure
are shown in Fig 1.
The channels of the chip were coated with a solution of 5% fibronectin (final concentration
50 μg/ml, Sigma Aldrich, St. Louis, Missouri, USA) dissolved in PBS (pH 7.4, KH2PO4 1.1
mM, NaCl 155 mM, Na2HPO4 3 mM, without CaCl2 and MgCl2, Life Technologies, Carlsbad,
USA) and incubated at 37˚C, CO2 5% for 60 min. In the meantime, passage 4–7 human umbil-
ical vein endothelial cells (HUVECs; catalogue number CC-2519, obtained directly from
Lonza in May 2015, Basel, Switzerland) were cultured to super-confluency (4.8x104 cells/cm2)
in endothelial cell growth medium (EGM-2, Lonza) in a T25 flask. The HUVECs were washed
twice with PBS (pH 7.4, KH2PO4 1.1 mM, NaCl 155 mM, Na2HPO4 3 mM, without CaCl2 and
MgCl2, Life Technologies) and trypsinized with 2 ml 0.05% trypsin in Hank’s balanced salt
solution containing 0.53 mM EDTA (Dow Corning). Subsequently, the trypsin was inactivated
with 9 ml EGM-2 and the cell suspension centrifuged at 1000 x g for 10 min. The pellet was
Fig 1. The microvascular flow model. (A) Polydimethylsiloxane chip (filled with a red dye for the purpose of making
the channels visible) in size comparison with a Swiss one franc coin (diameter of 2.32 cm). (B) Cartoon of a chip with
four parallel channels showing the tubings connecting pump and inlets, the outlets, and direction of flow.
https://doi.org/10.1371/journal.pone.0191292.g001
MASP-1 in a microvascular flow model
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resuspended in 80 μl EGM-2 containing dextran (80 mg/ml, 450–650 kDa; Sigma Aldrich) and
applied to a Falcon tube with a cell strainer cap (35 μm mesh size; Dow Corning) to avoid cell
clumping. The cells were then injected into the microchannels at a concentration of 1.2x106
per ml. The chip was incubated at 37˚C, 5% CO2 for 60 min before tubing (PTFE, inner diame-
ter 0.012 inch, outer diameter 0.03 inch; Cole-Parmer, Vernon Hills, Illinois, USA) was con-
nected to the channels and a constant EGM-2 flow of 2 μl/min was applied for 48 h. After two
days, the channels were checked by microscopy to determine if a viable endothelial cell mono-
layer with 95–100% confluency had been established.
Blood sampling
Whole blood (WB) from different healthy volunteers was freshly drawn into Sarstedt Monov-
ette1 tubes containing 0.106 mol/l sodium citrate (Sarstedt AG, Nu¨mbrecht, Germany) and
used for experiments within 60 min after blood sampling. The blood sampling was approved
by the ethics committee of the canton of Bern and all volunteers gave informed consent.
Clot formation experiments with rMASP-1
The channels of the chip were perfused with EGM-2 containing CellMask™ staining (final con-
centration 1 μl/ml, excitation/emission wavelengths 554/567 nm; Life Technologies) for 10
min at a flow rate of 2 μl/min to stain the endothelial cell monolayer. The citrated WB was sup-
plemented with prestained fibrinogen (final concentration 50 μg/ml, Alexa Fluor1 488 conju-
gate, excitation/emission 495/519 nm; Molecular Probes, Eugene, Oregon, USA) and
recalcified with CaCl2 (final concentration 12.5 mmol/l). An exemplary image of stained endo-
thelial cells and fibrin deposition is shown in Fig 2A. Immediately after recalcification, the WB
was supplemented with either rMASP-1cf (final concentration 10 μg/ml, 220 nmol/l) or
SGMI-1 (20.4 μg/ml, 5 μmol/l) and channels were perfused with the blood samples at a flow
rate of 2 μl/min and observed with confocal microscopy at 10x magnification (LSM 710 confo-
cal microscope with Zen software Version 2.1.; Carl Zeiss AG, Oberkochen, Germany). The
time from recalcification until the first appearance of immobilized fibrin in a channel was
recorded. The deposition of fibrin was used as a measurement for clot formation. For compari-
sons between groups, IBM SPSS Statistics Software Version 24 was used.
Complement activation and inhibition experiments
Freshly drawn citrated WB was supplemented with corn trypsin inhibitor (CTI, Haematologic
Technologies, Essex Junction, Vermont, USA) at a final concentration of 2.86 μmol/l (40 μg/
ml) to inhibit contact pathway activation during prolonged incubation of the blood. Subse-
quently, pre-activated zymosan (activation of zymosan by boiling in saline for 2 h, performed
by the manufacturer according to Minta et al., 1983 [28], final concentration 0.5 mg/ml,
CompTech, Tyler, Texas, USA), or the complement inhibitors rSALO (final concentration
5 μg/ml, 462 nmol/l) and/or SGMI-1 (final concentration 20.4 μg/ml, 5 μmol/l) were added to
the WB samples and incubated on a rotator at 8 rpm for 15 min at 37˚C. Subsequently, the
WB samples were recalcified and immediately thereafter used to perfuse the channels for time
course imaging (period of 18 min at cycles of 15 seconds) (Fig 2B). The images were evaluated
with ImageJ (Version 1.51k, Wayne Rasband, National Institute of Mental Health, Bethesa,
Maryland, USA) by measuring the fluorescence signal of immobilized fibrin within the chan-
nels over time. The results were displayed in graphs showing fluorescence intensity over time
(SigmaPlot 13.0, Systat Software Inc., San Jose, CA, USA).
MASP-1 in a microvascular flow model
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Results
Recently, we demonstrated that MASP-1 can activate coagulation factors and induce pro-
thrombin-dependent clot formation in isolated/purified systems [12,13]. The aim of the pres-
ent study was to investigate the relevance of MASP-1 and complement activation to clot
formation in a close-to-physiological environment. Here, we show for the first time in an
endothelialized, microvascular whole blood flow system that the action of MASP-1 and com-
plement activation enhance fibrin clot formation whereas their inhibition reduces or even
almost abolishes fibrin deposition.
Fig 2. Exemplary microscopic images of the flow model. (A) Endothelial cells stained in red and green-labelled fibrin
at 40x magnification. (B) Exemplary image taken at 10x magnification from a time course experiment, showing two
parallel channels perfused with whole blood in presence (top channel) or absence (bottom channel) of zymosan at 18
min after recalcification. Endothelial cells are stained in red, fibrin in green.
https://doi.org/10.1371/journal.pone.0191292.g002
MASP-1 in a microvascular flow model
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rMASP-1cf accelerates clot formation in the microvascular flow model
Endothelialized microchannels were perfused with WB freshly drawn from healthy donors.
Recalcified WB required an average of 16.3 min (SD 2.1 min, range 14–21 min, n = 9) to form
the first immobilized fibrin clots. Subsequently, the experiments were repeated using recalci-
fied WB samples supplemented with 10 μg/ml active rMASP-1cf. This resulted in an average
time to first fibrin clots of 11.6 min (SD 1.5 min, range 9–14 min, n = 8). Thus, as shown in Fig
3, MASP-1 accelerated fibrin formation significantly compared with recalcified WB only
(p<.001, Mann-Whitney test).
Inhibition of endogenous MASP-1 by SGMI-1 delays clot formation
In view of the recently reported finding that MASP-1 and MASP-2 are activated in the course
of clot formation [14], we wanted to evaluate to what extent endogenous MASP-1 (without
addition of rMASP-1cf) would affect clot formation in the microvascular flow model. There-
fore, microchannels were perfused with recalcified WB samples (n = 7) in the presence or
absence of the MASP-1 inhibitor SGMI-1. WB in the absence of SGMI-1 showed an average
fibrin clot formation time of 14.4 min (SD 2.44 min, range 11–18 min) while addition of
SGMI-1 yielded an average clotting time of 17.9 min (SD 2.79 min, range 14–21 min). Thus, as
shown in Fig 4, inhibition of endogenous MASP-1 by SGMI-1 was associated with a significant
delay in the appearance of first immobilized fibrin (p<0.02, Wilcoxon signed rank test).
Complement activation by zymosan increases clot formation
In a next step, we evaluated whether and in what manner activation of all three pathways of
the complement system by zymosan would affect whole blood clot formation in the microvas-
cular flow model. Five out of six samples (shown in S1 Fig) showed either earlier or more pro-
nounced fibrin formation in WB with zymosan compared to clot formation in recalcified WB
only. The variability observed in these experiments may—at least in part—be due to the indi-
vidual response to zymosan. As most human serum contains natural antibodies to yeast result-
ing in classical pathway activation [29], varying amounts of anti-zymosan antibodies may
result in a varying degree of complement activation. Other possible explanations include pre-
activation of complement or coagulation in individual donors or samples, or even artefacts
such as cellular particles occluding the channel. Overall, however, the results suggested that
complement activation by zymosan increased fibrin clot formation in WB.
Inhibition of the classical and/or lectin pathway reduces clot formation
In order to assess the individual contributions of the classical (CP) and lectin (LP) pathways,
we next investigated fibrin clot formation in WB with zymosan-activated complement in pres-
ence or absence of the CP inhibitor rSALO. Inhibition of the CP by rSALO showed a delayed
and reduced clot formation suggesting that the CP contributes to clot formation (Fig 5). Addi-
tion of both MASP-1 inhibitor SGMI-1 and rSALO to zymosan-activated WB did further
decrease and in some samples almost abolish clot formation (Fig 6), suggesting that the LP
does contribute to clot formation albeit the effect may be weaker compared with the CP. In
summary, these results showed that inhibition of CP and LP in zymosan-activated WB
reduced fibrin clot formation in our microvascular whole blood flow model.
Discussion
In recent years the crosstalk between the complement and the coagulation systems has moved
into the focus of interest. With more and more interactions being discovered, an overall
MASP-1 in a microvascular flow model
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picture emerges of two tightly interwoven, related systems standing in a firmly regulated bal-
ance. We and others have demonstrated that the lectin pathway protease MASP-1 affects the
coagulation system on various levels and promotes clot formation. However, many experi-
ments on the effects of MASP-1 on coagulation were conducted in isolated and static systems
such as plasma or with purified proteins in order to elucidate the underlying mechanisms.
Here we aimed at evaluating the role and relevance of MASP-1 and complement activation in
clot formation in a microvascular whole blood flow model which provides the closest model to
human physiology and thus the best human in vitro system. The parallel channels featured by
this model allow to simultaneously observe two blood samples under the same conditions,
making it an excellent tool to evaluate the effects of different activators and inhibitors on clot
formation. This setting also helps to reduce the impact of the inter- and intra-individual vari-
ability that is expected in a complex experimental environment with numerous influencing
factors, including the current physiological state and genetic predisposition of the individual.
For the first time we demonstrate in a microvascular flow model close to human physiol-
ogy, that addition of active rMASP-1cf significantly accelerates fibrin clot formation in WB
and that addition of the MASP-1 inhibitor SGMI-1 delays clot formation. In standard coagula-
tion assays (TT, PT, aPTT), SGMI-1 did not show any effects [26] which may be due to the
assay conditions. TT, PT and aPTT are accelerated by using coagulation activators which may
not leave enough time for endogenous MASP-1 activation and action.
The observed effects of rMASP-1cf on the coagulation are not surprising as MASP-1 has
been shown to directly activate prothrombin and FXIII and to interact with fibrinogen/fibrin,
Fig 3. Effect of mannan-binding lectin-associated serine protease-1 recombinant catalytic fragment (rMASP-1cf) on clot
formation in the microvascular whole blood flow model. The time from recalcification until the first appearance of
immobilized fibrin in a channel was recorded to measure the effect of rMASP-1cf on clot formation. Box plots represent the 25–
75% percentiles with the median shown as line. The whiskers represent the 10 and 90% percentiles.
https://doi.org/10.1371/journal.pone.0191292.g003
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platelets and endothelial cells [9,11–14,30]. Furthermore it is also known that downstream
complement molecules, such as MASP-2, C3a, C5a and the C5b-9, affect the coagulation sys-
tem, suggesting that MASP-1 has also indirect effects on coagulation via complement activa-
tion [31–33]. C3a, C5a and C5b-9 are part of the common complement pathway and can be
generated independently from the lectin pathway by the classical and alternative pathway [4].
Indeed it has been shown that the CP and the AP also affect coagulation [1–3]. This is in accor-
dance with our observation that inhibition of the CP by rSALO diminished clot formation in
the microvascular flow model.
Our results show that both LP and CP simultaneously affect coagulation as inhibition of
both pathways by SGMI-1 and rSALO almost suppresses clot formation. It is notable that inhi-
bition of the CP seems to have a stronger effect on the fibrin formation than inhibition of the
LP by SGMI-1-conferred MASP-1 blockage in zymosan-activated WB. It may point towards a
weaker effect of the LP on coagulation which is masked by the influence of the CP in an envi-
ronment where all complement pathways are active. The observed suppression of clot forma-
tion in presence of SGMI-1 and rSALO in zymosan supplemented blood also suggests that
zymosan itself does not significantly interact with the coagulation cascade in a direct manner.
Although it cannot be absolutely excluded as there still remains clot formation on a low level,
we assume that a direct effect of zymosan on the coagulation is negligible in this setting. Fur-
ther, one should also take into consideration that in the above assay zymogen-activated WB
was supplemented with the FXIIa inhibitor CTI to prevent contact pathway activation. While
in the context of recalcified WB with an intact contact pathway (without CTI) MASP-1
Fig 4. Effect of Schistocerca gregariaprotease inhibitor (SGPI)-based MASP inhibitor-1 (SGMI-1) on clot formation in the
microvascular whole blood flow model. The time from recalcification until the first appearance of immobilized fibrin in a
channel was recorded to measure the effect of SGMI-1 on clot formation. Box plots represent the 25–75% percentiles with the
median shown as line. The whiskers represent the 10 and 90% percentiles.
https://doi.org/10.1371/journal.pone.0191292.g004
MASP-1 in a microvascular flow model
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significantly contributed to clot formation, in the context of contact pathway inhibited WB
this contribution is diminished. This might suggest that MASP-1 exerts its procoagulant effect
at least in part through enhancing the contact pathway, and this contribution cannot manifest
when the contact pathway is blocked by CTI.
Although we consider the microvascular whole blood flow model closest to human physiol-
ogy and the best human in vitro system in regard to the presence of endothelial and blood
cells, a vessel structure and flow conditions, there are still limitations to be taken into account.
So far, the sample handling time and setup of the system did not allow the use of native, unci-
trated blood, which would be preferable as citrated/recalcified blood may have a tendency for
hypercoagulation [34]. A critical point is the cell confluency within the channels. Endothelial
cells in an incomplete monolayer may not exhibit their full anticoagulant properties, and sub-
endothelial structures may activate coagulation. It can be difficult to assess if channels are
100% confluent or not, as not every part of the device (especially the inlet area) can be thor-
oughly examined for uncovered patches. Yet, as both channels are seeded with the same num-
ber of endothelial cells from the same batch and are treated in the same way, we have rarely
seen a profound difference in confluency in our hands and we therefore judge the results
obtained in parallel channels as very comparable.
Conclusions
In conclusion, our work underpins the role of MASP-1 as an important link between the com-
plement and coagulation systems. We show for the first time in a microvascular whole blood
flow model that MASP-1 inhibition and especially inhibition of both LP and CP significantly
diminishes fibrin deposition upon complement activation. In healthy individuals, the
Fig 5. Effect of the classical pathway inhibitor recombinant salivary anti-complement from L. longipalpis (rSALO) on clot formation in whole
blood (WB) with an activated complement system. The amount of fibrin forming over time is expressed as fluorescence intensity of green-
fluorescent-labelled fibrinogen. Solid circles: Clot formation in zymosan-activated and recalcified WB without rSALO. Open circles: Clot formation in
zymosan-activated and recalcified WB in the presence of rSALO. (A)-(E) Results from five individual experiments. (F) Average clot formation of (A)-
(E) shown as mean (±SEM).
https://doi.org/10.1371/journal.pone.0191292.g005
MASP-1 in a microvascular flow model
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complement and coagulation systems are tightly regulated and pro-/anti-inflammatory and
pro-/anti-coagulant effects are well balanced. Under pathological conditions, e.g. sepsis, or ath-
erosclerosis and diabetes, where this balance is disturbed, the interactions between the two sys-
tems may promote the development of thrombotic complications. Complement activation in
general and the LP and MASP-1 in particular may represent promising targets for novel pre-
ventive and therapeutic strategies. Further research into complement-coagulation interactions
is clearly needed and the microvascular flow model can serve as a powerful tool in this field.
Supporting information
S1 Fig. Effect of zymosan-activated complement on clot formation. The amount of fibrin
forming over time is expressed as fluorescence intensity of green-fluorescent-labelled fibrino-
gen. Solid circles: Clot formation in recalcified whole blood with zymosan. Open circles: Clot
formation in recalcified whole blood without zymosan. (A)-(F) Results from six individual
experiments.
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supplemented with rSALO and SGMI-1. (A)-(E) Results from five individual experiments. (F) Average clot formation of (A)-(E) shown as mean
(±SEM).
https://doi.org/10.1371/journal.pone.0191292.g006
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